| Literature DB >> 17482130 |
Geoffrey D Girnun1, Elnaz Naseri, Scott B Vafai, Lishu Qu, Jeffrey D Szwaya, Roderick Bronson, John A Alberta, Bruce M Spiegelman.
Abstract
PPARgamma is a member of the nuclear receptor family for which agonist ligands have antigrowth effects. However, clinical studies using PPARgamma ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPARgamma activation with chemotherapeutic agents in current use for specific cancers. We observed a striking synergy between rosiglitazone and platinum-based drugs in several different cancers both in vitro and using transplantable and chemically induced "spontaneous" tumor models. The effect appears to be due in part to PPARgamma-mediated downregulation of metallothioneins, proteins that have been shown to be involved in resistance to platinum-based therapy. These data strongly suggest combining PPARgamma agonists and platinum-based drugs for the treatment of certain human cancers.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17482130 PMCID： PMC2564847 DOI： 10.1016/j.ccr.2007.02.025
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743